Latest Administration News

Franklin Templeton Australia has launched the Franklin Australian Absolute Return Bond Fund – Class A, an actively managed fixed income fund now available on the ASX. The fund aims to deliver returns exceeding the Bloomberg AusBond Bank Bill Index with a medium risk profile and transparent fee structure.

IPB Petroleum advances its key Browse Basin assets with ongoing drilling discussions and a strategic board appointment, while maintaining a solid cash position.

Fintech firm 8common has kicked off FY26 with an 8% rise in SaaS and transaction revenue, positive operational cashflow, and a renewed multi-year government contract.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Highfield Resources has secured a A$10 million convertible note investment from existing strategic shareholders following the collapse of a proposed strategic transaction with China Minmetals and Yankuang Energy. The company also received renewed institutional backing from the Government of Navarra for its flagship Muga Potash Project.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Insignia Financial reported a 3.1% rise in Funds Under Management and Administration to $340.5 billion, driven by strong net inflows into its Wrap platform and strategic enhancements to its MLC offerings. The company also completed a key custody transition and unveiled a refreshed MLC brand campaign.

Bellevue Gold Limited reported robust cash flow for the September quarter, enabling a substantial early repayment on its project loan and maintaining a strong cash position.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

Island Pharmaceuticals secures FDA confirmation that regulatory feedback on Galidesivir’s approval pathway will arrive on schedule, underscoring the drug’s strategic importance amid US government disruptions.

BlinkLab Limited has completed its U.S. pilot study for the Dx 1 smartphone-based autism diagnostic device, demonstrating strong accuracy and securing FDA alignment for its pivotal trial. The results mark a significant step toward transforming early neurodevelopmental diagnostics.

Patronus Resources Limited reported a significant boost in cash reserves to $7.1 million for Q3 2025, driven by strong investing activity despite ongoing operating cash outflows.